eFFECTOR Therapeutics nabs $40 mln Series B

By Iris Dorbian — 2 months ago

San Diego-based eFFECTOR Therapeutics, a biopharmaceutical company focused on treating cancer, has raised $40 million in Series B funding. The investors were Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital. In addition to the funding, eFFECTOR has named Dave Maki, managing partner of Altitude Life Science Ventures, to its board of directors.

Continue

Amplyx racks up $40.5 mln in RiverVest-led Series B round

By Iris Dorbian — 3 months ago

San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $40.5 million in Series B funding. RiverVest Venture Partners led the round with participation from other investors that included New Enterprise Associates and BioMed Ventures. In conjunction with the funding, Dr. Niall O’Donnell, managing director at RiverVest Venture Partners and Ed Mathers, a partner at New Enterprise Associates, were added to Amplyx’s board of directors.

Continue

VC-backed Edge Therapeutics goes public

By Iris Dorbian — 4 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has debuted its IPO after pricing its over 7.3 million shares at $11 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are serving as the lead underwriters. Edge Therapeutics’ backers included Venrock, Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures.

Continue

Syndax Pharmaceuticals racks up $80 mln Series C

By Iris Dorbian — 6 months ago

Waltham, Massachusetts-based Syndax Pharmaceuticals Inc, a biopharmaceutical company focused on treating cancer, has closed $80 million in Series C funding. Fidelity Management & Research Company and Delos Capital Fund LP led the round with participation from other investors that included EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures, Domain Associates, MPM Capital, RusnanoMedInvest and Forward Ventures.

Continue

Edge Therapeutics racks up about $72.5 mln

By Iris Dorbian — 10 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

Continue

Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO

By Iris Dorbian — 12 months ago

Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna’s board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.

Continue

VC-backed Zosano Pharma rolls out IPO

By Iris Dorbian — 1 year ago

Zosano Pharma Corp has launched its IPO after pricing its 4.5 million shares at $11 per share. The stock began trading Tuesday on the NASDAQ under the ticker symbol “ZSAN.” Ladenburg Thalmann and Roth Capital Partners are serving as lead underwriters. Based in Fremont, California, Zosano is a biopharmaceutical company focused on transdermal drug delivery. Its backers include Nomura International, BioMed Ventures, HBM BioVentures, New Enterprise Associates and ProQuest Investments.

Continue

Tracon Pharmaceuticals racks up $27 mln Series B

By Iris Dorbian — 1 year ago

Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo Securities were placement agents for the financing. In addition to the funding, Paul Walker of NEA has been added to Tracon’s board of directors while Bruce Steel of BioMed Ventures will become a board observer. Based in San Diego, Tracon develops treatments for cancer and age-related macular degeneration.

Continue

VC-backed Zosano files for IPO

By Iris Dorbian — 2 years ago

Zosano Pharma Corp. said Tuesday that it has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Based in Fremont, Calif., Zosano is a biopharmaceutical firm focused on transdermal drug delivery. Its backers include Nomura International, BioMed Ventures, HBM BioVentures, NEA and ProQuest Investments.

Continue

NanoString Technologies Completes Series E

By Angela Sormani — 3 years ago

NanoString Technologies, a provider of life science tools for translational research and developer of molecular diagnostic products, has completed a $15.3 million Series E Preferred Stock issuance. New investors in the transaction included Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. All previous venture investors participated including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, and Henri Termeer.

Continue

NanoString Technologies Appoints New CFO

By Angela Sormani — 3 years ago

NanoString Technologies, a provider of life science tools and developer of molecular diagnostics, has appointed James A. Johnson as the company’s new chief financial officer. Johnson assumes this role from Wayne Burns who will remain with the company in his new position as senior vice president, operations and administration. NanoString Technologies is backed by GE, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Continue

Histogenics Lines up Big-Name Life Sci VCs for Mega A-Round

By Jonathan Marino — 4 years ago

Waltham, Mass.-based regenerative medicine developer Histogenics Corp. wrapped up a $49 million Series A round, the company revealed Tuesday. Sofinnova Ventures led the big round, and was joined by a litany of backers: Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. invested for the first time, and were joined by ProChon Holdings BV, […]

Continue